Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her ...

Pediatric sarcomas are a significant category within pediatric malignancies, comprising over 20% of solid malignant cancers in children. These cancers are ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

By combining imaging and therapy in one targeted approach, researchers hope to select patients who will benefit from the targeted radiation and strike tumors more accurately, while overcoming the ...

Using bacteria to attack cancer cells is not a new idea, but the Waterloo researchers have engineered a solution to one of the biggest challenges inherent to the method.

BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...

Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, ...